📰 Resented News
Page 43 - Resented News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Resented. Real-time updates on events, politics, business and more.
June 11, 2022
Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell
June 11, 2022
Rapid and potent C5 inhibition achieved with complete and sustained blockage of complement by a single dose of CAN106 Data to be presented at the 14th International Conference on Complement
June 10, 2022
OSLO, Norway, June 10, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces an update from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan)
June 10, 2022
ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 10, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is
June 10, 2022
STOCKHOLM, June 10, 2022 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its leading candidate
June 8, 2022
Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June
June 7, 2022
China censored the country top e-commerce live streamer, Li Jiaqi, after he and his co-host presented the audience with a plate of Viennetta ice cream from th
June 6, 2022
InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that Professor Zhanguo Li, the leading PI, has presented latest data of BTK inhibitor orelabrutinib for the treatment of Systemic
June 5, 2022
Preliminary analysis of data from an ongoing investigator-initiated, single-center Phase 1 study supported by BioNTech and Genentech and conducted at Memorial Sloan Kettering Cancer Center, New York, United
June 3, 2022
12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of lifeTofersen also led to robust and sustained reductions